Welcome to our dedicated page for Revolution Medicines news (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines stock.
Revolution Medicines, Inc. develops targeted oncology therapies for patients with RAS-addicted cancers. Company news centers on its RAS(ON) inhibitor pipeline, including daraxonrasib, a RAS(ON) multi-selective inhibitor, and selective programs such as elironrasib, zoldonrasib and RMC-5127.
Recurring updates cover clinical data in pancreatic ductal adenocarcinoma, non-small cell lung cancer and other RAS-mutant solid tumors, presentations at oncology meetings, scientific publications, regulatory interactions and trial-stage progress. Revolution Medicines also reports quarterly financial results, financing activity and corporate progress tied to research and development, potential commercialization planning and its broader RAS(ON) discovery platform.
Revolution Medicines, Inc. (Nasdaq: RVMD) released its first quarter 2024 financial results and corporate progress update. The company is advancing its RAS-addicted cancer therapies, such as RMC-6236, into pivotal trials. Plans include expanding therapy reach, qualifying mutant-selective inhibitors, and exploring combination treatments. Despite revenue decline and increased expenses, the company aims to fund operations into 2027.
Revolution Medicines, Inc. (Nasdaq: RVMD) will report its financial results for the first quarter of 2024 on May 8, 2024, after market close. The company is focused on developing targeted therapies for patients with RAS-addicted cancers. A webcast hosted by senior management will discuss the financial results and corporate progress.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.